Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Read More Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Read More Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Read More Press release Stine Krag Brunvold 9/8/23 Press release Stine Krag Brunvold 9/8/23 NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association Read More Insights Stine Krag Brunvold 8/15/23 Insights Stine Krag Brunvold 8/15/23 Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Claus Read More Other news Stine Krag Brunvold 6/28/23 Other news Stine Krag Brunvold 6/28/23 We will be in Orlando, Florida from 28-30 June for the Annual SMA Research and Clinical Care Conference Read More Press release Stine Krag Brunvold 6/20/23 Press release Stine Krag Brunvold 6/20/23 NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Read More Press release Stine Krag Brunvold 6/9/23 Press release Stine Krag Brunvold 6/9/23 NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting Read More Press release Stine Krag Brunvold 6/1/23 Press release Stine Krag Brunvold 6/1/23 NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy Read More Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23 NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 Read More Other news Stine Krag Brunvold 5/9/23 Other news Stine Krag Brunvold 5/9/23 NMD Pharma to Attend Bio€quity Europe 2023 Read More Other news Stine Krag Brunvold 3/7/23 Other news Stine Krag Brunvold 3/7/23 We will be in Basel for BIO-Europe Spring Read More Events Stine Krag Brunvold 2/28/23 Events Stine Krag Brunvold 2/28/23 Rare Disease Day, 28 February 2023 Read More Other news Stine Krag Brunvold 1/4/23 Other news Stine Krag Brunvold 1/4/23 Meet us at J.P. Morgan Healthcare Conference on January 9-12, 2023 in San Francisco Read More Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23 Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Read More Press release Stine Krag Brunvold 12/14/22 Press release Stine Krag Brunvold 12/14/22 NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Read More Other news Stine Krag Brunvold 12/7/22 Other news Stine Krag Brunvold 12/7/22 Thomas Holm Pedersen, will be participating in the 7th Annual Nordic American Life Science Conference Read More Other news Stine Krag Brunvold 12/3/22 Other news Stine Krag Brunvold 12/3/22 Today is International Day of Persons with Disabilities Read More Other news Stine Krag Brunvold 11/24/22 Other news Stine Krag Brunvold 11/24/22 We have been awarded Entrepreneur of the Year in the Life Sciences category by EY Denmark! Read More Other news Stine Krag Brunvold 11/24/22 Other news Stine Krag Brunvold 11/24/22 NMD Pharma will be at the Life Science Career Fair Aarhus 22 Read More Newer Posts Older Posts
Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Read More
Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Read More
Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Read More
Press release Stine Krag Brunvold 9/8/23 Press release Stine Krag Brunvold 9/8/23 NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association Read More
Insights Stine Krag Brunvold 8/15/23 Insights Stine Krag Brunvold 8/15/23 Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Claus Read More
Other news Stine Krag Brunvold 6/28/23 Other news Stine Krag Brunvold 6/28/23 We will be in Orlando, Florida from 28-30 June for the Annual SMA Research and Clinical Care Conference Read More
Press release Stine Krag Brunvold 6/20/23 Press release Stine Krag Brunvold 6/20/23 NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Read More
Press release Stine Krag Brunvold 6/9/23 Press release Stine Krag Brunvold 6/9/23 NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting Read More
Press release Stine Krag Brunvold 6/1/23 Press release Stine Krag Brunvold 6/1/23 NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy Read More
Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23 NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 Read More
Other news Stine Krag Brunvold 5/9/23 Other news Stine Krag Brunvold 5/9/23 NMD Pharma to Attend Bio€quity Europe 2023 Read More
Other news Stine Krag Brunvold 3/7/23 Other news Stine Krag Brunvold 3/7/23 We will be in Basel for BIO-Europe Spring Read More
Events Stine Krag Brunvold 2/28/23 Events Stine Krag Brunvold 2/28/23 Rare Disease Day, 28 February 2023 Read More
Other news Stine Krag Brunvold 1/4/23 Other news Stine Krag Brunvold 1/4/23 Meet us at J.P. Morgan Healthcare Conference on January 9-12, 2023 in San Francisco Read More
Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23 Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Read More
Press release Stine Krag Brunvold 12/14/22 Press release Stine Krag Brunvold 12/14/22 NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Read More
Other news Stine Krag Brunvold 12/7/22 Other news Stine Krag Brunvold 12/7/22 Thomas Holm Pedersen, will be participating in the 7th Annual Nordic American Life Science Conference Read More
Other news Stine Krag Brunvold 12/3/22 Other news Stine Krag Brunvold 12/3/22 Today is International Day of Persons with Disabilities Read More
Other news Stine Krag Brunvold 11/24/22 Other news Stine Krag Brunvold 11/24/22 We have been awarded Entrepreneur of the Year in the Life Sciences category by EY Denmark! Read More
Other news Stine Krag Brunvold 11/24/22 Other news Stine Krag Brunvold 11/24/22 NMD Pharma will be at the Life Science Career Fair Aarhus 22 Read More
